Alchemab Therapeutics
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.
Alchemab Therapeutics has raised €98M across 3 funding rounds from 8 investors, most recently a Series A round in Jul 2026. Based in London, UK; founded 2019; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€98M
€98,317,274
Funding rounds
3
Investors
8
distinct backers
Active since
2021-04
latest 2026-07
Funding by year
EUR raised per year · 2026 YTDAlchemab Therapeutics — funding by year — interactive chart.
Data table
| Alchemab Therapeutics — funding by year | |
|---|---|
| 2021 | €69M |
| 2025 | €0 |
| 2026 | €29M |
Signals
High confidenceRaise-next likelihood21
base rate 44% for Series A
- ▼ Raised very recently
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood24
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▲ 7y since founding (typical exit age)
- ▲ Recent equity round, but funding momentum is down (may be rescue financing)
Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-07-09 | Series A | €29M | British Business Bank | View deal → |
| 2025-09-09 | Series A | — | DCVC Bio,Lightstone Ventures,Lilly,Ono Venture Investment (OVI),RA Capital,SV Health Investors | View deal → |
| 2021-04-15 | Series A | €69M | RA Capital Management | View deal → |